If you want a Stock Review on IVC, RMD, SYK, or ZBH then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. For today, DailyStockTracker.com scans four equities to see how they have fared at the close of the last trading session: Invacare Corp. (NYSE: IVC), ResMed Inc. (NYSE: RMD), Stryker Corp. (NYSE: SYK), and Zimmer Biomet Holdings Inc. (NYSE: ZBH). Medical Appliances and Equipment companies primarily offer equipment and devices, which are designed for diagnosis, monitoring, and treatment of patients in healthcare systems worldwide. This equipment ranges greatly in complexity and function.  Register now and get full and free access to these DailyStockTracker.com research reports at:

http://dailystocktracker.com/register/

Invacare 

On Thursday, shares in Elyria, Ohio headquartered Invacare Corp. recorded a trading volume of 527,317 shares. The stock ended at $14.60, rising 3.91% from the last trading session. The Company’s shares have gained 6.57% over the previous three months and 11.88% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 0.47% and 10.54%, respectively. Furthermore, shares of Invacare, which together with its subsidiaries, designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets worldwide, have a Relative Strength Index (RSI) of 45.89. Access our complete research report on IVC for free at:

http://dailystocktracker.com/registration/?symbol=IVC

ResMed 

San Diego, California headquartered ResMed Inc.’s stock finished yesterday’s session 1.36% higher at $77.59 with a total trading volume of 554,084 shares. The Company’s shares have gained 25.04% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.80% and 7.21%, respectively. Furthermore, shares of ResMed, which develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases, have an RSI of 55.22.  

On September 25th, 2017, research firm Barclays reiterated its ‘Underweight’ rating on the Company’s stock with an increase of the target price from $65 a share to $68 a share.

On September 28th, 2017, ResMed announced that it will report its Q1 FY18 results on October 26th, 2017, after the NYSE market closes. A press release with Company results will be issued that same day after 1:00 p.m. US PT. Furthermore, the Company will host a live webcast at 1:30 p.m. US PT to discuss its operating results and future outlook. The earnings webcast can be accessed on the Company’s Investor Relations website. The complimentary research report on RMD can be downloaded at:

http://dailystocktracker.com/registration/?symbol=RMD

Stryker 

At the close of trading on Thursday, shares in Kalamazoo, Michigan headquartered Stryker Corp. climbed 0.10%, ending the day at $146.56. The stock recorded a trading volume of 813,923 shares. The Company’s shares have advanced 2.47% in the last one month, 0.80% in the previous three months, and 22.33% since the start of this year. The stock is trading 2.16% and 7.93% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Stryker, which together with its subsidiaries, operates as a medical technology company, have an RSI of 56.14. Register for free on DailyStockTracker.com and get access to the latest report on SYK at:

http://dailystocktracker.com/registration/?symbol=SYK

Zimmer Biomet Holdings 

Warsaw, Indiana headquartered Zimmer Biomet Holdings Inc.’s shares ended the day 1.68% higher at $120.63. A total volume of 1.50 million shares was traded, which was above their three months average volume of 1.44 million shares. The stock has gained 4.09% in the last month and 16.89% on an YTD basis. The Company’s shares are trading 4.84% above their 50-day moving average and 1.46% above their 200-day moving average. Additionally, shares of Zimmer Biomet, which together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, Middle-East, Africa, and Asia/Pacific, have an RSI of 65.79.  

On October 10th, 2017, Zimmer Biomet announced that its Q3 sales and earnings conference call will be broadcast over the Internet on November 01st, 2017, at 8:00 a.m. ET. A news release detailing the quarterly results will be made available at 7:00 a.m. ET that same day. The audio webcast of the call can be accessed on the Company’s Investor Relations website. Download your free research report on ZBH at:

http://dailystocktracker.com/registration/?symbol=ZBH

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@dailystocktracker.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://dailystocktracker.com/disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If youre a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE dailystocktracker.com

Powered by WPeMatico